$BFNH
BIOFORCE NANOSCIENCES HOLDINGS, INC.

2023 Q2 Form 10-Q Financial Statement

#000109181823000071 Filed on May 09, 2023

View on sec.gov

Income Statement

Concept 2023 Q2 2023 Q1 2022 Q1
Revenue $0.00
YoY Change
Cost Of Revenue
YoY Change
Gross Profit
YoY Change
Gross Profit Margin
Selling, General & Admin $113.9K $130.0K $132.4K
YoY Change -1.6% -1.81% -8.73%
% of Gross Profit
Research & Development
YoY Change
% of Gross Profit
Depreciation & Amortization
YoY Change
% of Gross Profit
Operating Expenses $113.9K $130.0K $132.4K
YoY Change -1.6% -1.82% -8.73%
Operating Profit -$113.9K -$130.0K -$132.4K
YoY Change -1.6% -1.82% -8.73%
Interest Expense
YoY Change
% of Operating Profit
Other Income/Expense, Net $23.01K
YoY Change
Pretax Income -$113.9K -$130.0K -$132.4K
YoY Change -1.6% -1.81% -8.73%
Income Tax
% Of Pretax Income
Net Earnings -$113.9K -$130.0K -$132.4K
YoY Change -1.6% -1.82% -8.73%
Net Earnings / Revenue
Basic Earnings Per Share $0.00 $0.00
Diluted Earnings Per Share $0.00 $0.00 -$4.523K
COMMON SHARES
Basic Shares Outstanding 29.27M shares 29.27M shares 29.27M shares
Diluted Shares Outstanding 29.27M shares 29.27M shares

Balance Sheet

Concept 2023 Q2 2023 Q1 2022 Q1
SHORT-TERM ASSETS
Cash & Short-Term Investments $650.00 $690.00 $11.11K
YoY Change -92.96% -93.79% -65.11%
Cash & Equivalents $654.00 $686.00 $11.11K
Short-Term Investments
Other Short-Term Assets $10.00
YoY Change -91.67%
Inventory
Prepaid Expenses
Receivables
Other Receivables
Total Short-Term Assets $654.00 $686.00 $11.12K
YoY Change -92.91% -93.83% -65.21%
LONG-TERM ASSETS
Property, Plant & Equipment
YoY Change
Goodwill
YoY Change
Intangibles
YoY Change
Long-Term Investments
YoY Change
Other Assets
YoY Change
Total Long-Term Assets $0.00 $0.00 $0.00
YoY Change
TOTAL ASSETS
Total Short-Term Assets $654.00 $686.00 $11.12K
Total Long-Term Assets $0.00 $0.00 $0.00
Total Assets $654.00 $686.00 $11.12K
YoY Change -92.91% -93.83% -65.21%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable $1.140K $1.600K $0.00
YoY Change 185.0% -100.0%
Accrued Expenses $1.385M $1.279M $856.3K
YoY Change 43.97% 49.4% 97.63%
Deferred Revenue
YoY Change
Short-Term Debt $0.00 $0.00 $0.00
YoY Change
Long-Term Debt Due
YoY Change
Total Short-Term Liabilities $1.592M $1.478M $1.005M
YoY Change 42.22% 47.0% 87.24%
LONG-TERM LIABILITIES
Long-Term Debt $0.00 $0.00 $0.00
YoY Change
Other Long-Term Liabilities
YoY Change
Total Long-Term Liabilities $0.00 $0.00 $0.00
YoY Change
TOTAL LIABILITIES
Total Short-Term Liabilities $1.592M $1.478M $1.005M
Total Long-Term Liabilities $0.00 $0.00 $0.00
Total Liabilities $1.592M $1.478M $1.005M
YoY Change 42.22% 47.0% 87.24%
SHAREHOLDERS EQUITY
Retained Earnings -$160.4M -$160.3M
YoY Change 0.3%
Common Stock $158.8M $158.8M
YoY Change 0.0%
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity -$1.591M -$1.477M -$994.3K
YoY Change
Total Liabilities & Shareholders Equity $654.00 $686.00 $11.12K
YoY Change -92.91% -93.83% -65.21%

Cashflow Statement

Concept 2023 Q2 2023 Q1 2022 Q1
OPERATING ACTIVITIES
Net Income -$113.9K -$130.0K -$132.4K
YoY Change -1.6% -1.82% -8.73%
Depreciation, Depletion And Amortization
YoY Change
Cash From Operating Activities -$8.650K -$23.05K -$32.94K
YoY Change -10.18% -30.01% 1.82%
INVESTING ACTIVITIES
Capital Expenditures
YoY Change
Acquisitions
YoY Change
Other Investing Activities $0.00 $0.00
YoY Change
Cash From Investing Activities
YoY Change
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net
YoY Change
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities 8.610K $23.01K 32.94K
YoY Change 11.1% -30.16% 35.44%
NET CHANGE
Cash From Operating Activities -8.650K -$23.05K -32.94K
Cash From Investing Activities
Cash From Financing Activities 8.610K $23.01K 32.94K
Net Change In Cash -40.00 -$48.00 $0.00
YoY Change -97.87%
FREE CASH FLOW
Cash From Operating Activities -$8.650K -$23.05K -$32.94K
Capital Expenditures
Free Cash Flow
YoY Change

Facts In Submission

Frame Concept Type Concept / XBRL Key Value Unit
CY2023Q1 dei Entity Central Index Key
EntityCentralIndexKey
0001310488
CY2023Q1 dei Amendment Flag
AmendmentFlag
false
CY2023Q1 dei Current Fiscal Year End Date
CurrentFiscalYearEndDate
--12-31
CY2023Q1 dei Document Fiscal Year Focus
DocumentFiscalYearFocus
2023
CY2023Q1 dei Document Fiscal Period Focus
DocumentFiscalPeriodFocus
Q1
CY2023Q1 us-gaap Cost Of Revenue
CostOfRevenue
usd
CY2023Q1 us-gaap Gross Profit
GrossProfit
usd
CY2023Q1 us-gaap Increase Decrease In Prepaid Expense
IncreaseDecreaseInPrepaidExpense
usd
CY2023Q1 us-gaap Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
usd
CY2022Q1 us-gaap Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
usd
CY2022Q1 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
usd
CY2023Q1 us-gaap Interest Paid Net
InterestPaidNet
usd
CY2022Q1 us-gaap Interest Paid Net
InterestPaidNet
usd
CY2023Q1 us-gaap Income Taxes Paid Net
IncomeTaxesPaidNet
usd
CY2022Q1 us-gaap Income Taxes Paid Net
IncomeTaxesPaidNet
usd
CY2023Q1 dei Document Type
DocumentType
10-Q
CY2023Q1 dei Document Quarterly Report
DocumentQuarterlyReport
true
CY2023Q1 dei Document Period End Date
DocumentPeriodEndDate
2023-03-31
CY2023Q1 dei Document Transition Report
DocumentTransitionReport
false
CY2023Q1 dei Entity File Number
EntityFileNumber
000-51074
CY2023Q1 dei Entity Registrant Name
EntityRegistrantName
BIOFORCE NANOSCIENCES HOLDINGS, INC.
CY2023Q1 dei Entity Incorporation State Country Code
EntityIncorporationStateCountryCode
NV
CY2023Q1 dei Entity Tax Identification Number
EntityTaxIdentificationNumber
74-3078125
CY2023Q1 dei Entity Address Address Line1
EntityAddressAddressLine1
2020 General Booth Blvd.
CY2023Q1 dei Entity Address Address Line2
EntityAddressAddressLine2
Unit 230
CY2023Q1 dei Entity Address City Or Town
EntityAddressCityOrTown
Virginia Beach
CY2023Q1 dei Entity Address State Or Province
EntityAddressStateOrProvince
VA
CY2023Q1 dei Entity Address Postal Zip Code
EntityAddressPostalZipCode
23454
CY2023Q1 dei City Area Code
CityAreaCode
757
CY2023Q1 dei Local Phone Number
LocalPhoneNumber
306-6090
CY2023Q1 dei Entity Current Reporting Status
EntityCurrentReportingStatus
Yes
CY2023Q1 dei Entity Interactive Data Current
EntityInteractiveDataCurrent
Yes
CY2023Q1 dei Entity Filer Category
EntityFilerCategory
Non-accelerated Filer
CY2023Q1 dei Entity Small Business
EntitySmallBusiness
true
CY2023Q1 dei Entity Emerging Growth Company
EntityEmergingGrowthCompany
false
CY2023Q1 dei Entity Shell Company
EntityShellCompany
false
CY2023Q2 dei Entity Common Stock Shares Outstanding
EntityCommonStockSharesOutstanding
29271755 shares
CY2023Q1 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
686 usd
CY2022Q4 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
734 usd
CY2023Q1 us-gaap Assets Current
AssetsCurrent
686 usd
CY2022Q4 us-gaap Assets Current
AssetsCurrent
734 usd
CY2023Q1 us-gaap Assets
Assets
686 usd
CY2022Q4 us-gaap Assets
Assets
734 usd
CY2023Q1 us-gaap Accounts Payable And Accrued Liabilities Current
AccountsPayableAndAccruedLiabilitiesCurrent
1599 usd
CY2022Q4 us-gaap Accounts Payable And Accrued Liabilities Current
AccountsPayableAndAccruedLiabilitiesCurrent
398 usd
CY2023Q1 us-gaap Accrued Salaries Current And Noncurrent
AccruedSalariesCurrentAndNoncurrent
1279267 usd
CY2022Q4 us-gaap Accrued Salaries Current And Noncurrent
AccruedSalariesCurrentAndNoncurrent
1173517 usd
CY2023Q1 bfnh Due To Related Parties
DueToRelatedParties
197102 usd
CY2022Q4 bfnh Due To Related Parties
DueToRelatedParties
174096 usd
CY2023Q1 us-gaap Liabilities Current
LiabilitiesCurrent
1477968 usd
CY2022Q4 us-gaap Liabilities Current
LiabilitiesCurrent
1348011 usd
CY2023Q1 us-gaap Liabilities
Liabilities
1477968 usd
CY2022Q4 us-gaap Liabilities
Liabilities
1348011 usd
CY2023Q1 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.001
CY2022Q4 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.001
CY2023Q1 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
900000000 shares
CY2022Q4 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
900000000 shares
CY2023Q1 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
29271755 shares
CY2023Q1 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
29271755 shares
CY2022Q4 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
29271755 shares
CY2022Q4 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
29271755 shares
CY2023Q1 us-gaap Common Stock Value
CommonStockValue
29272 usd
CY2022Q4 us-gaap Common Stock Value
CommonStockValue
29272 usd
CY2023Q1 us-gaap Additional Paid In Capital Common Stock
AdditionalPaidInCapitalCommonStock
158781227 usd
CY2022Q4 us-gaap Additional Paid In Capital Common Stock
AdditionalPaidInCapitalCommonStock
158781127 usd
CY2023Q1 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-160287781 usd
CY2022Q4 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-160157776 usd
CY2023Q1 us-gaap Stockholders Equity
StockholdersEquity
-1477282 usd
CY2022Q4 us-gaap Stockholders Equity
StockholdersEquity
-1347277 usd
CY2023Q1 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
686 usd
CY2022Q4 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
734 usd
CY2023Q1 us-gaap Compensation Expense Excluding Cost Of Good And Service Sold
CompensationExpenseExcludingCostOfGoodAndServiceSold
105750 usd
CY2022Q1 us-gaap Compensation Expense Excluding Cost Of Good And Service Sold
CompensationExpenseExcludingCostOfGoodAndServiceSold
105750 usd
CY2023Q1 us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
24255 usd
CY2022Q1 us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
26658 usd
CY2023Q1 us-gaap Operating Expenses
OperatingExpenses
130005 usd
CY2022Q1 us-gaap Operating Expenses
OperatingExpenses
132408 usd
CY2023Q1 us-gaap Net Income Loss
NetIncomeLoss
-130005 usd
CY2022Q1 us-gaap Net Income Loss
NetIncomeLoss
-132408 usd
CY2023Q1 bfnh Weighted Average Number Of Common Shares Basic And Diluted
WeightedAverageNumberOfCommonSharesBasicAndDiluted
29271755 shares
CY2022Q1 bfnh Weighted Average Number Of Common Shares Basic And Diluted
WeightedAverageNumberOfCommonSharesBasicAndDiluted
29271755 shares
CY2023Q1 bfnh Net Loss Per Common Shares Basic And Diluted
NetLossPerCommonSharesBasicAndDiluted
-0.00
CY2022Q1 bfnh Net Loss Per Common Shares Basic And Diluted
NetLossPerCommonSharesBasicAndDiluted
-0.00
CY2023Q1 us-gaap Net Income Loss
NetIncomeLoss
-130005 usd
CY2022Q1 us-gaap Net Income Loss
NetIncomeLoss
-132408 usd
CY2022Q1 us-gaap Increase Decrease In Prepaid Expense
IncreaseDecreaseInPrepaidExpense
-30 usd
CY2023Q1 us-gaap Increase Decrease In Accounts Payable And Accrued Liabilities
IncreaseDecreaseInAccountsPayableAndAccruedLiabilities
1201 usd
CY2022Q1 us-gaap Increase Decrease In Accounts Payable And Accrued Liabilities
IncreaseDecreaseInAccountsPayableAndAccruedLiabilities
-6313 usd
CY2023Q1 us-gaap Increase Decrease In Accrued Salaries
IncreaseDecreaseInAccruedSalaries
105750 usd
CY2022Q1 us-gaap Increase Decrease In Accrued Salaries
IncreaseDecreaseInAccruedSalaries
105750 usd
CY2023Q1 us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-23054 usd
CY2022Q1 us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-32941 usd
CY2023Q1 us-gaap Proceeds From Related Party Debt
ProceedsFromRelatedPartyDebt
23006 usd
CY2022Q1 us-gaap Proceeds From Related Party Debt
ProceedsFromRelatedPartyDebt
32941 usd
CY2023Q1 us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
23006 usd
CY2022Q1 us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
32941 usd
CY2023Q1 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
-48 usd
CY2022Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
734 usd
CY2021Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
11105 usd
CY2023Q1 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
686 usd
CY2022Q1 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
11105 usd
CY2021Q4 us-gaap Stockholders Equity
StockholdersEquity
-861863 usd
CY2022Q1 us-gaap Net Income Loss
NetIncomeLoss
-132408 usd
CY2022Q1 us-gaap Stockholders Equity
StockholdersEquity
-994271 usd
CY2022Q4 us-gaap Stockholders Equity
StockholdersEquity
-1347277 usd
CY2023Q1 us-gaap Net Income Loss
NetIncomeLoss
-130005 usd
CY2023Q1 us-gaap Stockholders Equity
StockholdersEquity
-1477282 usd
CY2020Q2 bfnh Business Acquisition Equity Interests Purchased Number Of Shares
BusinessAcquisitionEquityInterestsPurchasedNumberOfShares
100000 shares
CY2020Q2 us-gaap Payments To Acquire Businesses Gross
PaymentsToAcquireBusinessesGross
1000 usd
CY2023Q1 us-gaap Use Of Estimates
UseOfEstimates
<p id="xdx_840_eus-gaap--UseOfEstimates_zHoyy4awNfH6" style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><span id="xdx_863_zZMJuY2kKIje">Use of Estimates</span></b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The preparation of financial statements in conformity with generally accepted accounting principles in the United States of America requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the financial statements and the reported amounts of revenues and expenses during the reporting period. Actual results could differ from those estimates.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p>
CY2023Q1 bfnh Expenses
Expenses
23006 usd
CY2022Q1 bfnh Expenses
Expenses
32941 usd
CY2023Q1 bfnh Due To Related Parties
DueToRelatedParties
197102 usd
CY2022Q4 bfnh Due To Related Parties
DueToRelatedParties
174096 usd
CY2023Q1 us-gaap Preferred Stock Shares Authorized
PreferredStockSharesAuthorized
100000000 shares
CY2022Q4 us-gaap Preferred Stock Shares Authorized
PreferredStockSharesAuthorized
100000000 shares
CY2023Q1 us-gaap Preferred Stock Par Or Stated Value Per Share
PreferredStockParOrStatedValuePerShare
0.001
CY2022Q4 us-gaap Preferred Stock Par Or Stated Value Per Share
PreferredStockParOrStatedValuePerShare
0.001
CY2023Q1 us-gaap Preferred Stock Conversion Basis
PreferredStockConversionBasis
Preferred stock can be converted into 100 shares of common stock, have dividend rights at 100 times common and have voting rights equal to 100 shares of common stock.
CY2023Q1 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
900000000 shares
CY2022Q4 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
900000000 shares
CY2023Q1 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.001
CY2022Q4 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.001
CY2019Q4 us-gaap Stockholders Equity Reverse Stock Split
StockholdersEquityReverseStockSplit
5 to 1 reverse split
CY2023Q1 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
29271755 shares
CY2023Q1 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
29271755 shares
CY2022Q4 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
29271755 shares
CY2022Q4 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
29271755 shares

Files In Submission

Name View Source Status
bfnh-20230331_cal.xml Edgar Link unprocessable
0001091818-23-000071-index-headers.html Edgar Link pending
0001091818-23-000071-index.html Edgar Link pending
0001091818-23-000071.txt Edgar Link pending
0001091818-23-000071-xbrl.zip Edgar Link pending
bfnh-20230331.xsd Edgar Link pending
bfnh20230331.htm Edgar Link pending
bfnh-20230331_def.xml Edgar Link unprocessable
bfnh-20230331_lab.xml Edgar Link unprocessable
bfnh-20230331_pre.xml Edgar Link unprocessable
bfnh20230331_htm.xml Edgar Link completed
bfnhlogo2019001.jpg Edgar Link pending
ex311.htm Edgar Link pending
ex312.htm Edgar Link pending
ex321.htm Edgar Link pending
ex322.htm Edgar Link pending
Financial_Report.xlsx Edgar Link pending
MetaLinks.json Edgar Link pending
R1.htm Edgar Link pending
R10.htm Edgar Link pending
R11.htm Edgar Link pending
R12.htm Edgar Link pending
R13.htm Edgar Link pending
R14.htm Edgar Link pending
R15.htm Edgar Link pending
R16.htm Edgar Link pending
R2.htm Edgar Link pending
R3.htm Edgar Link pending
R4.htm Edgar Link pending
R5.htm Edgar Link pending
R6.htm Edgar Link pending
R7.htm Edgar Link pending
R8.htm Edgar Link pending
R9.htm Edgar Link pending
report.css Edgar Link pending
Show.js Edgar Link pending
FilingSummary.xml Edgar Link unprocessable